Will regulators catch up in 2020?
The industry will always find ways to slip through legal loopholes. Will regulators catch up in 2020?
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Home » Editor's note
Browsing Category
Editor’s note
Rationalising pharma trade margins seems next on the list
Wide price deviation between countries offering cheaper medications indicates the complexity of drug pricing strategies across…
Lupin sells stakes in Kyowa but its not a Sayonara
With headwinds in overseas markets, it is vital for pharma companies in India to grow their presence in the domestic market. But…
After sartans and ranitidine, where will NDMA show up next?
While regulators and pharma companies try to understand if it is the product or the process that is at fault in the ranitidine…
Slaying GMP non-compliance woes
Multiple warning letters call for renewed rigour to fix recurring lapses and instil a stronger quality compliance system
Heeding the clarion call for sustainability
New and existing pharma facilities will have to meet higher benchmarks to ensure that they do not pollute the environment…
Price caps are a band aid hiding larger issues
Pharma companies should not be the ones held responsible for the high prices of medicines
CDSCO is blowin’ in the wind
The CBI has reportedly found cases with the same modus operandi: failing batches and then approving them for a price
Big Pharma to get bigger, but what about patients?
The second patent cliff is around the corner, as patents for branded molecules with cumulative global sales of over $ 251 billion…
Protect IP to grow GDP
The RCEP negotiation is one of the BJP-led NDA-2 government’s first challenges as it links directly to the stated goal to make…